A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL.

IF 2 4区 医学 Q3 HEMATOLOGY Hematology Pub Date : 2024-12-01 Epub Date: 2024-05-22 DOI:10.1080/16078454.2024.2356300
Xueying Wang, Yan Deng, Guangcui He, Sihan Lai, Yecheng Li, Shan Zhang, Ying He, Ying Han, Lilan Zhang, Yi Su, Fang Liu, Hai Yi
{"title":"A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL.","authors":"Xueying Wang, Yan Deng, Guangcui He, Sihan Lai, Yecheng Li, Shan Zhang, Ying He, Ying Han, Lilan Zhang, Yi Su, Fang Liu, Hai Yi","doi":"10.1080/16078454.2024.2356300","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) are highly malignant and aggressive hematologic tumors for which there is no standard first-line treatment. Chidamide, a novel histone deacetylase inhibitor, shows great promise. We assessed the efficacy and safety of an irradiation-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and post-transplantation chidamide maintenance in patients with T-ALL/LBL.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical data of six patients with T-ALL/LBL who underwent allo-HSCT with a radiotherapy-containing pretreatment regimen and post-transplant chidamide maintenance therapy. The endpoints were relapse, graft-versus-host disease (GVHD), transplant-related mortality (TRM), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).</p><p><strong>Results: </strong>All of the patients had uneventful post-transplant hematopoietic reconstitution, and all achieved complete molecular remission within 30 days. All six patients survived, and two relapsed with a median relapse time of 828.5 (170-1335) days. The 1-year OS rate was 100%, the 2-year PFS rate was 66.7%, and the TRM rate was 0%. After transplantation, two patients developed grade I-II acute GVHD (2/6); grade III-IV acute and chronic GVHD were not observed. The most common AEs following chidamide administration were hematological AEs, which occurred to varying degrees in all patients; liver function abnormalities occurred in two patients (grade 2), and symptoms of malaise occurred in one patient (grade 1).</p><p><strong>Conclusion: </strong>Chidamide maintenance therapy after T-ALL/LBL transplantation is safe, but the efficacy needs to be further investigated.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2356300"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2024.2356300","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) are highly malignant and aggressive hematologic tumors for which there is no standard first-line treatment. Chidamide, a novel histone deacetylase inhibitor, shows great promise. We assessed the efficacy and safety of an irradiation-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and post-transplantation chidamide maintenance in patients with T-ALL/LBL.

Methods: We retrospectively analyzed the clinical data of six patients with T-ALL/LBL who underwent allo-HSCT with a radiotherapy-containing pretreatment regimen and post-transplant chidamide maintenance therapy. The endpoints were relapse, graft-versus-host disease (GVHD), transplant-related mortality (TRM), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).

Results: All of the patients had uneventful post-transplant hematopoietic reconstitution, and all achieved complete molecular remission within 30 days. All six patients survived, and two relapsed with a median relapse time of 828.5 (170-1335) days. The 1-year OS rate was 100%, the 2-year PFS rate was 66.7%, and the TRM rate was 0%. After transplantation, two patients developed grade I-II acute GVHD (2/6); grade III-IV acute and chronic GVHD were not observed. The most common AEs following chidamide administration were hematological AEs, which occurred to varying degrees in all patients; liver function abnormalities occurred in two patients (grade 2), and symptoms of malaise occurred in one patient (grade 1).

Conclusion: Chidamide maintenance therapy after T-ALL/LBL transplantation is safe, but the efficacy needs to be further investigated.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对T-ALL/LBL采用基于辐照的调理方案和利多酰胺维持疗法的回顾性研究。
治疗目标T细胞急性淋巴细胞白血病/淋巴细胞淋巴瘤(T-ALL/LBL)是高度恶性的侵袭性血液肿瘤,目前尚无标准的一线治疗方法。新型组蛋白去乙酰化酶抑制剂 Chidamide 前景广阔。我们评估了T-ALL/LBL患者异基因造血干细胞移植(allo-HSCT)中含辐照的调理方案和移植后奇达胺维持治疗的有效性和安全性:我们回顾性分析了接受异基因造血干细胞移植(allo-HSCT)的6例T-ALL/LBL患者的临床数据,这些患者接受了含放疗的预处理方案和移植后的奇达酰胺维持治疗。研究终点为复发、移植物抗宿主病(GVHD)、移植相关死亡率(TRM)、无进展生存期(PFS)、总生存期(OS)和不良事件(AEs):结果:所有患者移植后造血重建顺利,并在30天内实现了完全分子缓解。六名患者全部存活,两名患者复发,中位复发时间为 828.5 (170-1335) 天。1年OS率为100%,2年PFS率为66.7%,TRM率为0%。移植后,两名患者出现了I-II级急性GVHD(2/6);未观察到III-IV级急性和慢性GVHD。服用利多酰胺后最常见的不良反应是血液学不良反应,所有患者都出现了不同程度的不良反应;2名患者出现肝功能异常(2级),1名患者出现乏力症状(1级):结论:T-ALL/LBL 移植后的氯达酰胺维持治疗是安全的,但疗效有待进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hematology
Hematology 医学-血液学
CiteScore
2.60
自引率
5.30%
发文量
140
审稿时长
3 months
期刊介绍: Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.
期刊最新文献
Clinical characteristics and prognostic analysis of CDKN2A/2B gene in pediatric acute lymphoblastic leukemia: a retrospective case-control study. IGHG4: innovative diagnostic biomarkers for iron overload in β-thalassemia patients. Treatment of Pediatric Acute Lymphoblastic Leukemia in India as per modified BFM 95 protocol with Minimal Residual Disease monitoring. Malnutrition defined by Controlling Nutritional Status score was independently associated with prognosis of diffuse large B-cell lymphoma primarily on elderly patients. Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1